Supernus Pharma (SUPN) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Supernus Pharma (SUPN) Tops Q1 EPS by 19c
May 9, 2022 4:06 PM EDT
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter 2022, a 38% increase compared to fourth quarter 2021GOCOVRI® prescriptions in first quarter 2022... More
May 9, 2022 4:05 PM EDT
First quarter 2022 total revenues of $152.5 million, a 16% increase compared to first quarter 2021First quarter 2022 net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectivelyFirst quarter 2022 GAAP operating income of $2.0 million; first quarter 2022 non-GAAP operating income of $28.0 millionU.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adultsQelbree continued its growth trajectory, with 47,324 prescriptions in first quarter 2022, a 38% increase compared to fourth quarter 2021GOCOVRI® prescriptions in first quarter 2022 reached 10,736, a 23%... More
